Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has been given a $12.00 target price by Guggenheim in a research note issued on Monday. The brokerage currently has a a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 149.48% from the stock’s previous close.
Separately, Chardan Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Aralez Pharmaceuticals in a research note on Friday, September 16th.
Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) traded down 2.83% on Monday, hitting $4.81. 573,721 shares of the stock traded hands. The company’s market cap is $313.81 million. The stock has a 50 day moving average of $5.26 and a 200 day moving average of $4.21. Aralez Pharmaceuticals has a one year low of $3.10 and a one year high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business earned $12.60 million during the quarter, compared to analysts’ expectations of $9.70 million. The firm’s revenue was up 142.3% on a year-over-year basis. Equities analysts anticipate that Aralez Pharmaceuticals will post ($1.06) earnings per share for the current year.
In related news, Director Robert Paul Harris sold 150,000 shares of the firm’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the sale, the director now directly owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.77% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in ARLZ. Bank of Montreal Can purchased a new stake in Aralez Pharmaceuticals during the second quarter valued at about $100,000. Advisor Group Inc. purchased a new stake in Aralez Pharmaceuticals during the second quarter valued at about $118,000. Knott David M bought a new stake in shares of Aralez Pharmaceuticals during the second quarter worth $124,000. Alpine Partners VI LLC bought a new stake in shares of Aralez Pharmaceuticals during the second quarter worth $133,000. Finally, LMR Partners LLP bought a new stake in shares of Aralez Pharmaceuticals during the second quarter worth $145,000. Hedge funds and other institutional investors own 49.63% of the company’s stock.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.